Minocycline

The selection of clinical treatment regimens for drug-resistant bacterial infections has always been a core concern in the field of infectious diseases. As a representative variety of the second-generation semi-synthetic tetracycline antibiotics, minocycline exerts broad-spectrum antibacterial activity by reversibly binding to the 30S subunit of bacterial ribosomes to block peptide chain elongation, and has a strong inhibitory effect on a variety of pathogens such as Gram-positive bacteria, Gram-negative bacteria, *Propionibacterium acnes*, mycoplasma and chlamydia. In addition to being clinically used for respiratory, biliary, urinary tract and skin and soft tissue infections caused by susceptible bacteria, it is also one of the first-line therapeutic drugs for moderate to severe acne and rosacea. Meanwhile, it can be used for the treatment of special infected populations with rickettsial diseases, non-gonococcal urethritis and other conditions, and has a very wide range of application scenarios in the diagnosis and treatment of adult infectious diseases.

At present, the global market size of minocycline is approximately USD 2.1 billion, and the compound annual growth rate from 2023 to 2028 is expected to remain at 4.2%. The growth momentum mainly comes from the rising prevalence of acne, the expanding demand for the treatment of drug-resistant bacterial infections and the promotion of sustained-release dosage forms. In terms of the Chinese market, the annual sales of minocycline at public medical institution terminals have exceeded RMB 1.8 billion, of which oral dosage forms account for more than 92%. Currently, there are more than 30 domestic enterprises with approved minocycline preparations. After the implementation of volume-based procurement, the market share of generic drugs has risen to 78%, and the supply of API is dominated by local enterprises, with a significant import substitution trend. There is no unverified data for now.

The original developer of minocycline is Pfizer, and the original brand name is "Minocin". Its core compound patent expired globally in 2002, and the subsequent patent for the sustained-release dosage form also expired in the United States in 2018. The originally marketed dosage forms include 50mg and 100mg conventional tablets and sustained-release capsules, which have been included in the *Catalogue of Reference Preparations of Chemical Drugs* of China, and are also included in the FDA Reference Preparation Catalogue. Up to now, there are 26 minocycline API registration records in the API registration platform of China National Medical Products Administration Center for Drug Evaluation (CDE), of which 18 are in the status of "A (approved for use in marketed preparations)". A number of domestic enterprises have obtained marketing approval for minocycline tablets and capsules. (Data as of April 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of minocycline impurity reference standards, which can meet the impurity research requirements of different synthetic process routes. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. Meanwhile, the products meet the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, providing reliable reference standard support for pharmaceutical enterprises in the links of quality research, stability testing and registration declaration.